Page 5 of 20
Solid pharmaceutical compositions for treating HCV
15 Feb 22
The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2.
Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
Filed: 16 Oct 19
8 Feb 22
The present invention features crystalline forms of Compound I.
Jean-Christophe Califano, Michael G. Fickes, Lars Fredrik Nordstroem
Filed: 4 Dec 17
Wearable Automatic Injection Device for Controlled Administration of Therapeutic Agents
27 Jan 22
Exemplary embodiments provide wearable automatic injection devices for administering a therapeutic agent to a patient's body at fast, controlled rates, for example, in a single fast bolus.
Philip D. Anderson, Joseph F. Julian, Linas P. Laurusonis, Sean Corrigan, William Fienup, Tomas Matusaitis, Chris Strahm
Filed: 1 Mar 21
Methods for Treating Spinal Cord Injury and Pain
27 Jan 22
Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.
Bernhard Klaus MUELLER, Peer B. JACOBSON
Filed: 9 Mar 21
20 Jan 22
Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
Filed: 24 Feb 21
Monoclonal Antibodies Against Amyloid Beta Protein and Uses Thereof
20 Jan 22
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
Filed: 22 Feb 21
20 Jan 22
The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.
Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
Filed: 16 Jul 21
RGMa Fragment Based Diagnostic Assay
20 Jan 22
Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample.
Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
Filed: 2 Mar 21
Combination Therapy of a Type II ANTI-CD20 Antibody with a Selective BCL-2 Inhibitor
13 Jan 22
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother
Filed: 5 Mar 21
Medicine Container, Method of Assembling the Container, and Method of Dispensing the Medicine from the Container
13 Jan 22
A child-resistant medication container assembly that includes a blister card including a plurality of compartments each configured to support a dosage of medication, and a puck including a body portion, a recess that defines a partition wall in the body portion, and a plurality of openings defined in the partition wall.
Todd Marshall, Bhimaprasad Medhal, John G. Finch, Joy Elizabeth Borgardt
Filed: 13 May 21
Inhibitors of Bruton's Tyrosine Kinase
13 Jan 22
Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk).
Lee Honigberg, Erik J. Verner, Zhengying Pan
Filed: 19 Feb 21
HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
13 Jan 22
The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer.
Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
Filed: 16 Feb 21
Apoptosis-inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
30 Dec 21
Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.
Zhi-Fu Tao, Xilu Wang, Michael Wendt, Andrew Souers, Andrew Judd, Aaron Kunzer, Gerard Sullivan
Filed: 4 Feb 21
Modulators of the Integrated Stress Pathway
23 Dec 21
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Kathleen J. Murauski
Filed: 2 Nov 18
Methods of Treating Acute HCV
16 Dec 21
The present invention features interferon-free therapies for the treatment of acute HCV.
Gail Matthews, Gregory Dore, Mark Nelson, Fernando Franciosi, Ana Gabriela Pires Dos Santos
Filed: 20 Nov 19
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
14 Dec 21
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
Filed: 14 Apr 21
Syringe with Two-stage Sealing Pressure
9 Dec 21
A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel.
Sean E. Mackey, Ji Zhou, Martin J. Gibler, Dennis Y. Lee
Filed: 15 Jan 21
Methods of Treatment of Diseases In Which IL-13 Activity Is Detrimental Using ANTI-IL-13 Antibodies
9 Dec 21
The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
Gregg TIMONY, Sheila GUJRATHI, Robert PEACH, Allan OLSON
Filed: 27 Apr 17
Protein formulations and methods of making same
7 Dec 21
The invention provides an aqueous formulation comprising water and a protein, and methods of making the same.
Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
Filed: 29 Dec 20
Inhibitors of ROR gamma
30 Nov 21
The present disclosure relates to salts and crystalline forms of a compound having the formula (I): Also described are processes for the production of the salts and crystalline forms described herein.
Chaoyi Deng, Jun He, Bo Xu
Filed: 24 Jul 18